Discovery of an inhibitor of Z-alpha1 antitrypsin polymerization

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Berthelier, Valerie ^a,b   Harris, Jason Brett ^b,c,d   Estenson, Kasey Noel ^a,b   Baudry, Jerome ^b,c  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; NITROBENZYLTHIOGUANOSINE; UNCLASSIFIED DRUG; Z ALPHA 1 ANTITRYPSIN; 6-THIOGUANOSINE; GUANOSINE; MOLECULAR LIBRARY; NUCLEOSIDE; PROTEIN BINDING;

ARTICLE; BETA SHEET; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR WEIGHT; PREDICTION; PROTEIN AGGREGATION; PROTEIN POLYMERIZATION; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HUMAN; IC50; MOLECULAR LIBRARY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BINDING SITES; DRUG DISCOVERY; GUANOSINE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SMALL MOLECULE LIBRARIES; THIONUCLEOSIDES;

EID: 84930637088     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126256     Document Type: Article

References (45)

1. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988;84:13-31. Available: http://www.ncbi.nlm.nih.gov/pubmed/3289385 PMID: 3289385
2. Gooptu B, Dickens JA, Lomas DA. The molecular and cellular pathology of a1-antitrypsin deficiency. Trends Mol Med. 2014;20:116-27. doi: 10.1016/j.molmed.2013.10.007 PMID: 24374162
3. Perlmutter DH. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu Rev Med. 2011;62:333-45. doi: 10.1146/annurev-med-042409-151920 PMID: 20707674
4. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature; Nat. 2000;407:923-926. doi: 10.1038/35038119 PMID: 11057674
5. Whisstock JC, Bottomley SP. Molecular gymnastics: serpin structure, folding and misfolding. CurrOpin Struct Biol. 2006;16:761-768. doi: 10.1016/j.sbi.2006.10.005 PMID: 17079131
6. Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA. A kinetic mechanism for the polymerization of alpha1-antitrypsin. J BiolChem. 1999;274:9548-9555. PMID: 10092640
7. Lomas DA. Loop-sheet polymerization: the mechanism of alpha1-antitrypsin deficiency. Respir Med. 2000;94 Suppl C:S3-6. PMID: 10954247
8. De Serres FJ, Blanco I. Prevalence of a1-antitrypsin deficiency alleles PI∗Sand PI∗Z worldwide and effective screening for each of the five phenotypic classes PI∗MS, PI∗MZ, PI∗SS, PI∗SZ, and PI∗ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6:277-95. doi: 10.1177/1753465812457113 PMID: 22933512
9. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. New Engl J Med New Engl J Med. 1986;314:736-739. PMID: 3485248
10. An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of alphalAT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatol (Baltimore, Md); Hepatol (Baltimore, Md). 2005;41:160-167. doi: 10.1002/hep. 20508
11. Hussain M, Mieli-Vergani G, Mowat AP. Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment. J Inherit Metab Dis J Inherit Metab Dis. 1991;14:497-511. PMID: 1749215
12. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80:1366-74. doi: 10.1172/JCI113214 PMID: 3500183
13. Lomas DA, Evans DL, Stone SR, Chang WS, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochem (John Wiley Sons); Biochem. 1993;32:500-508.
14. Elliott PR, Bilton D, Lomas DA. Lung polymers in Zalpha (1)-antitrypsin deficiency-related emphysema. Am J RespirCell Mol Biol. 1998;18:670-674. PMID: 9569237
15. Mahadeva R, Atkinson C, Li Z, Stewart S, Janciauskiene S, Kelley DG, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol. 2005;166:377-386. PMID: 15681822
16. Parmar JS, Mahadeva R, Reed BJ, Farahi N, Cadwallader KA, Keogan MT, et al. Polymers of alpha (1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J RespirCell Mol Biol. 2002;26:723-730. PMID: 12034572
17. Lomas DA, Perlmutter DH, Uversky VN. Alpha-1 Antitrypsin Deficiency. In: Ramirez-Alvarado M, Kelly JW, Dobson CM, editors. Protein Misfolding Diseases-Current and Emerging Principles and Therapies. Hoboken, New Jersey: A John Wiley & Sons, Inc.; 2010. pp. 403-424.
18. Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha (1)-antitryp-sin-related cirrhosis. J Biol Chem. 2002;277:6771-6774. doi: 10.1074/jbc. C100722200 PMID: 11773044
19. Gooptu B, Hazes B, Chang WS, Dafforn TR, Carrell RW, Read RJ, et al. Inactive conformation of the serpin alpha (1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA. 2000;97:67-72. PMID: 10618372
20. Purkayastha P, Klemke JW, Lavender S, Oyola R, Cooperman BS, Gai F. Alpha 1-antitrypsin polymerization: a fluorescence correlation spectroscopic study. Biochemistry. 2005;44:2642-2649. doi: 10. 1021/bi048662e PMID: 15709777
21. Ekeowa UI, Freeke J, Miranda E, Gooptu B, Bush MF, Perez J, et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci USA. 2010;107:17146-17151. doi: 10.1073/pnas.1004785107 PMID: 20855577
22. Yamasaki M, Li W, Johnson DJ, Huntington JA. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature. 2008;455:1255-1258. doi: 10.1038/nature07394 PMID: 18923394
23. Yamasaki M, Sendall TJ, Pearce MC, Whisstock JC, Huntington JA. Molecular basis of alpha1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep. 2011;12:1011-1017. doi: 10.1038/embor.2011.171; PMID: 21909074
24. Miranda E, Pérez J, Ekeowa UI, Hadzic N, Kalsheker N, Gooptu B, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. Hepatology. 2010;52:1078-88. doi: 10.1002/hep. 23760 PMID: 20583215
25. Ekeowa UI, Freeke J, Miranda E, Gooptu B, Bush MF, Pérez J, et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci USA. 2010;107:17146-51. doi: 10.1073/pnas. 1004785107 PMID: 20855577
26. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha1-AT deficiency. Proc Natl Acad Sci USA. 2000;97:1796-1801. PMID: 10677536
27. Devlin GL, Parfrey H, Tew DJ, Lomas DA, Bottomley SP. Prevention of polymerization of M and Z alpha1-Antitrypsin (alpha1-AT) with trimethylamine N-oxide. Implications for the treatment of alpha1-at deficiency. Am J RespirCell Mol Biol. 2001;24:727-732. PMID: 11415938
28. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr. 2004;39:34-37. PMID: 15187777
29. Mallya M, Phillips RL, Saldanha SA, Gooptu B, Leigh SC, Termine DJ, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem. 2007;50:5357-5363. doi: 10.1021/jm070687z PMID: 17918823
30. Parfrey H, Mahadeva R, Ravenhill NA, Zhou A, Dafforn TR, Foreman RC, et al. Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease. J Biol Chem. 2003;278:33060-33066. doi: 10.1074/jbc. M302646200 PMID: 12807889
31. Makarananda K, Neal GE. Competitive ELISA. Methods Mol Biol. 1992;10:267-72. doi: 10.1385/0-89603-204-3:267 PMID: 23150318
32. Pearce MC, Morton CJ, Feil SC, Hansen G, Adams JJ, Parker MW, et al. Preventing serpin aggregation: The molecular mechanism of citrate action upon antitrypsin unfolding. Protein Sci. 2008;17:2127-2133. doi: 10.1110/ps.037234.108 PMID: 18780818
33. Elliott PR, Pei XY, Dafforn TR, Lomas DA. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci a Publ Protein Soc. 2000;9:1274-1281. doi: 10.1110/ps.9.7.1274
34. Chemical Computing Group-Citing MOE [Internet]. 2012. Available: http://www.chemcomp. com/Research-Citing MOE.htm
35. Labute P. Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins Struct Funct Bioinforma. 2009;75:187-205. doi: 10.1002/prot.22234
36. Halgren T. A. (1999) OBForce Field MMFF94. J. Comput. Chem. 20 720-729. No Title.
37. Labute P. The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem. 2008;29:1693-1698. doi: 10.1002/jcc.20933 PMID: 18307169
38. Gooptu B, Miranda E, Nobeli I, Mallya M, Purkiss A, Brown SCL, et al. Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design. J Mol Biol. Elsevier Ltd; 2009;387:857-68. doi: 10.1016/j.jmb.2009.01.069 PMID: 19232354
39. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane database Syst Rev. 2010; CD007851. doi: 10.1002/14651858. CD007851.pub2 PMID: 20614465
40. Leeson P. Drug discovery: Chemical beauty contest. Nature. Nature Publishing Group; 2012;481:455-6. doi: 10.1038/481455a PMID: 22281594
41. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357:605-607. doi: 10.1038/357605a0 PMID: 1608473
42. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet. 2002;3:759-68. doi: 10.1038/nrg907 PMID: 12360234
43. Alam S, Wang J, Janciauskiene S, Mahadeva R. Preventing and reversing the cellular consequences of Z alpha-1 antitrypsin accumulation by targeting s4A. J Hepatol. European Association for the Study of the Liver; 2012;57:116-24. doi: 10.1016/j.jhep. 2012.02.025
44. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA. Ensemble-Based Virtual Screening Reveals Potential Novel Antiviral Compounds for Avian Influenza Neuraminidase. J Med Chem. 2008;51:3878-3894. doi: 10.1021/jm8001197 PMID: 18558668
45. Demir Ö, Baronio R, Salehi F, Wassman CD, Hall L, Hatfield GW, et al (2011) Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comp.